Page last updated: 2024-10-23

aspirin and Atresia, Pulmonary

aspirin has been researched along with Atresia, Pulmonary in 2 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Avlonitis, VS1
Planas, S1
Hayes, AM1
Parry, A1
Romlin, BS1
Wåhlander, H1
Strömvall-Larsson, E1
Synnergren, M1
Baghaei, F1
Jeppsson, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age[NCT00833703]Phase 349 participants (Actual)Interventional2009-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants According to Bleeding Type/Etiology

For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. (NCT00833703)
Timeframe: Up to a maximum of 6 months

,
Interventionparticipants (Number)
SpontaneousPuncture (vascular access site)
Clopidogrel 0.2 mg/kg/Day11
Placebo00

Number of Participants With Bleeding Events

"All bleeding events experienced during the study period were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted." (NCT00833703)
Timeframe: Up to a maximum of 6 months

,
Interventionparticipants (Number)
Any bleeding event- Serious- Serious with an outcome of death- Leading to permanent treatment discontinuation
Clopidogrel 0.2 mg/kg/Day2000
Placebo0000

Number of Participants With Shunt Thrombosis Requiring Intervention or Deaths

"Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded.~Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first)." (NCT00833703)
Timeframe: Up to a maximum of 6 months

,
Interventionparticipants (Number)
shunt thrombosis requiring interventiondeath
Clopidogrel 0.2 mg/kg/Day00
Placebo01

Other Studies

2 other studies available for aspirin and Atresia, Pulmonary

ArticleYear
Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:2

    Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Clopidogrel; Fatal Outcome; Graft Occlusion, Vas

2012
Monitoring of acetyl salicylic acid-induced platelet inhibition with impedance aggregometry in children with systemic-to-pulmonary shunts.
    Cardiology in the young, 2013, Volume: 23, Issue:2

    Topics: Aspirin; Blalock-Taussig Procedure; Double Outlet Right Ventricle; Electric Impedance; Female; Heart

2013